NSE: PPLPHARMA | BSE: 543635

Momentum Trap

Download real time

203.47 -7.88 (-3.73%)

New 52W High in past week

3.3M NSE+BSE Volume

NSE 15 Sep, 2026 3:31 PM (IST)

27,088.9

Market Cap

High in industry

Beta 1Year

High Volatility

US FDA Observation

Piramal Pharma gets a Form 483 with 7 observations from US FDA after a GMP inspection at UK unit See details

Piramal Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PPLPHARMA, BSE:543635 Piramal Pharma Ltd.

Search Inside the pdf :

Piramal Pharma Ltd.

31 Jul 2026

203.47

-3.73%

Entering next growth orbit

Buy: Piramal Pharma Ltd.

Target

ICICI Securities Limited

Piramal Pharma (Piramal)’s upbeat performance in Q1FY27 (revenue up 17.4%) stemmed from solid traction across segments (+15–19%) and currency benefit; thus, enabling a 308bps expansion in EBITDA margins to 8.6%.

Piramal Pharma Ltd. is trading above its 200 day SMA of 172.7

Piramal Pharma Ltd.

30 Jul 2026

203.47

-3.73%

Broad-based growth drives improved operational performance

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered better-than-expected revenue/EBITDA (7%/41% beat) for 1QFY27. The company also reported a lower-than-expected loss, supported by higher other income.

Piramal Pharma Ltd. has an average target of 238.33 from 3 brokers.

Piramal Pharma Ltd.

30 Jul 2026

203.47

-3.73%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

: Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates in 3 major segments. Contract development and manufacturing organisations (CDMO) Complex hospital generics (critical care)...

Piramal Pharma has gained 24.18% in the last 3 Months

Piramal Pharma Ltd.

30 Apr 2026

203.47

-3.73%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

Normalisation expected from FY27- Overall performance was largely in line with expectations. The CDMO business was impacted by de-stocking; adjusting for this, the segment delivered healthy double-digit revenue growth in Q4. Improving biopharma funding is also translating into stronger RFP momentum and a pickup in order inflows for the CDMO segment. Management is also focusing on Cost Optimization & Operational Excellence which should help improve profitability of the segment going forward. The CHG business was affected by the postponement of certain...

Piramal Pharma has gained 24.18% in the last 3 Months

Piramal Pharma Ltd.

29 Apr 2026

203.47

-3.73%

Operationally below est.; ends FY26 on a weak note

Buy: Piramal Pharma Ltd.

Motilal Oswal

Piramal Pharma (PIRPHARM) posted in-line revenue for 4QFY26. The EBITDA was lower than expected (an 8% miss), primarily due to a product mix change.

Piramal Pharma has gained 45.53% in the last 6 Months

Piramal Pharma Ltd.

30 Jan 2026

203.47

-3.73%

Piramal Pharma

Buy: Piramal Pharma Ltd.

Target

ICICI Direct

PPL owns 17 development and manufacturing facilities across India, US and UK with capabilities in sterile, API, formulations, drug discovery and manufacturing of nutrition products. The company holds 49% stake in AbbVie Therapeutics, JV with...

FII/FPI have decreased holdings from 30.17% to 12.51% in Jun 2026 qtr

Piramal Pharma Ltd.

29 Jan 2026

203.47

-3.73%

3Q below estimates; trough phase extends

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma posted a miss on revenue/EBITDA in 3QFY26, affected by low traction in CDMO business. Complex hospital generics (CHG) business was largely stable YoY, with regulatory delays keeping growth in check.

Piramal Pharma Ltd. is trading below its 30 day SMA of 212.2

Piramal Pharma Ltd.

06 Nov 2025

203.47

-3.73%

2Q – A miss; higher opex drags earnings

Buy: Piramal Pharma Ltd.

Motilal Oswal

Piramal Pharma (PIRPHARM) delivered in-line revenue for 2QFY62. However, it delivered a miss on EBITDA/PAT for the quarter. Higher operational costs impacted the quarter’s performance.

Piramal Pharma has gained 24.18% in the last 3 Months

Piramal Pharma Ltd.

29 Jul 2025

203.47

-3.73%

Near-term weak due to the muted CHG business

Buy: Piramal Pharma Ltd.

Target

Motilal Oswal

Piramal Pharma (PIRPHARM) exhibited lower-than-expected financial performance in 1QFY26. Lower CDMO and complex hospital generics (CHG) sales led to a considerable operating deleverage.

Piramal Pharma has gained 24.18% in the last 3 Months

Piramal Pharma Ltd.

29 Jul 2025

203.47

-3.73%

Temporary slowdown before a sprint

Buy: Piramal Pharma Ltd.

Target

ICICI Securities Limited

Piramal Pharma’s (Piramal) Q1FY26 result was below our expectations. Performance was impacted due to lack of revenue from a large innovative CDMO (-5.7% YoY) molecule and delay in shipment timing in CHG business (grew 1%).

Piramal Pharma has gained 24.18% in the last 3 Months

VOTE: Is Piramal Pharma Ltd. worth buying?

409 Votes:

Buy 83.13%

Sell 10.76%

Hold 6.11%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf